Evidence map›Paper›PMID 28326251›Full record

ArticleJournal of kidney cancer and VHL2014

Targeted Therapy for Metastatic Renal Carcinoma: an Update.

Rodrigo Donalisio da Silva, Diedra Gustafson, Leticia Nogueira, Priya N Werahera, Wilson R Molina, Fernando J Kim

Open access · diamondAbstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in Journal of kidney cancer and VHL, 2014. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 4 papers.

0numbers the graph read from it
0cells of the map it votes in
4citing papers in PubMed
1.0field-weighted citation impact, top 22% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

4 citing papers in PubMed, 9 citations in OpenAlex.

  1. Article
  2. Article
  3. Review
  4. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

6 authors at 3 institutions in 1 country.

Rodrigo Donalisio da SilvaDepartment of Urology, Denver Health Medical Center, Denver, Colorado, USA; Department of Pathology and Department of Bioengineering, University of Colorado Denver, Aurora, Colorado, USA; University of Colorado Cancer Center Denver, University of Colorado Denver, Denver, Colorado, USA.
Diedra GustafsonDepartment of Urology, Denver Health Medical Center, Denver, Colorado, USA; Department of Pathology and Department of Bioengineering, University of Colorado Denver, Aurora, Colorado, USA; University of Colorado Cancer Center Denver, University of Colorado Denver, Denver, Colorado, USA.
Leticia NogueiraDepartment of Urology, Denver Health Medical Center, Denver, Colorado, USA; Department of Pathology and Department of Bioengineering, University of Colorado Denver, Aurora, Colorado, USA; University of Colorado Cancer Center Denver, University of Colorado Denver, Denver, Colorado, USA.
Priya N WeraheraDepartment of Urology, Denver Health Medical Center, Denver, Colorado, USA; Department of Pathology and Department of Bioengineering, University of Colorado Denver, Aurora, Colorado, USA; University of Colorado Cancer Center Denver, University of Colorado Denver, Denver, Colorado, USA.
Wilson R MolinaDepartment of Urology, Denver Health Medical Center, Denver, Colorado, USA; Department of Pathology and Department of Bioengineering, University of Colorado Denver, Aurora, Colorado, USA; University of Colorado Cancer Center Denver, University of Colorado Denver, Denver, Colorado, USA.
Fernando J KimDepartment of Urology, Denver Health Medical Center, Denver, Colorado, USA; Department of Pathology and Department of Bioengineering, University of Colorado Denver, Aurora, Colorado, USA; University of Colorado Cancer Center Denver, University of Colorado Denver, Denver, Colorado, USA.
University of Colorado Denver · USDenver Health Medical Center · USUniversity of Colorado Cancer Center · US

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Conventional chemotherapy is associated with poor outcomes in metastatic renal cell carcinoma (RCC). Advances in the understanding of tumor molecular biology and the implementation of new drugs that target these molecular pathways have increased the arsenal against advanced RCC and improved outcomes in these patients. Herein, we briefly describe the latest data on targeted therapies used in the treatment of advanced renal cell carcinoma. Search strategy was performed according to PRISMA guidelines. Abstracts of relevant studies published in PubMed between 2000 and 2014 were analyzed by two authors. Abstracts were selected if they were published in English, data reported was of phase II or III clinical trials, and outcomes followed FDA approval. If consensus between the two authors was achieved, they were included in the review. Key words used were "target therapy" and "metastatic renal cell carcinoma". The results of the studies analyzed in this review support the benefits of targeted therapy in metastatic RCC. These include improved progression-free survival, overall survival, and quality of life as well as reduced toxicities compared to immunotherapy. The improvement in outcomes in metastatic RCC makes these drugs a preferred option as a primary treatment for these patients.

Identifiers

PMID28326251
PMCPMC5345523
OpenAlexW2070963861

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.